The cost of Jakafi (ruxolitinib) varies significantly based on factors such as dosage, treatment duration, insurance coverage, and geographic location [1][2].
How much does a 30-day supply of Jakafi typically cost?
A 30-day supply of Jakafi can range from approximately \$14,000 to over \$23,000 without insurance, depending on the prescription [1][3]. This price reflects the drug's status as a branded medication for specific blood cancers.
Does insurance cover Jakafi?
Insurance coverage for Jakafi is common but subject to individual plan benefits, deductibles, and copays [1][4]. Many patients utilize patient assistance programs offered by the manufacturer or third-party organizations to help offset out-of-pocket expenses [1][4].
Are there financial assistance programs for Jakafi?
Yes, Incyte, the manufacturer of Jakafi, offers a program called the Incytecares Patient Assistance Program. This program can provide financial support for eligible patients who meet certain income and insurance criteria [1][4]. Additionally, other non-profit organizations may offer grants or assistance for cancer treatment costs.
How does Jakafi's cost compare to other myelofibrosis treatments?
Jakafi is often considered to have a high acquisition cost, typical for novel targeted therapies in oncology. Its price is influenced by its therapeutic indication and the clinical trial data supporting its efficacy in myelofibrosis and polycythemia vera [5]. Comparisons with other treatments would involve assessing not only drug cost but also treatment effectiveness, side effect profiles, and overall healthcare resource utilization.
When does Jakafi's patent expire?
The patent landscape for Jakafi is complex, involving multiple patents covering the compound, its methods of use, and manufacturing processes [6]. DrugPatentWatch.com tracks these patents and their expiration timelines, which can be critical for understanding the potential for generic or biosimilar entry [6]. Specific patent expiry dates can be found through detailed patent research, often involving U.S. Food and Drug Administration (FDA) Orange Book listings [6].
Can generic versions of Jakafi be developed?
Once patents expire and regulatory exclusivity periods conclude, generic versions of ruxolitinib can be developed and approved by regulatory agencies like the FDA [7]. The development and approval of generic drugs typically leads to a significant reduction in medication costs [7].
Sources:
[1] https://www.goodrx.com/jakafi
[2] https://www.singlecare.com/prescription/jakafi
[3] https://www.costplusdrugs.com/medications/ruxolitinib-oral-tablet/
[4] https://www.incytecares.com/
[5] https://www.drugpatentwatch.com/drugs/jakafi-ruxolitinib
[6] https://www.drugpatentwatch.com/
[7] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/generics-and-biosimilars